Wells Fargo Initiates Coverage on Dianthus Therapeutics

Analysts set 'overweight' rating and $135 price target for biotech firm.

Mar. 19, 2026 at 1:24pm

Got story updates? Submit your updates here. ›

Stock analysts at Wells Fargo & Company have initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH), issuing an 'overweight' rating and a $135.00 price target on the stock. This target price represents a potential upside of 71.19% from the company's current trading price.

Why it matters

The initiation of coverage by a major investment bank like Wells Fargo is a significant event for a clinical-stage biotech company like Dianthus Therapeutics. It signals that Wall Street analysts see strong potential in the company's pipeline and future prospects.

The details

In their note to investors, the Wells Fargo analysts cited Dianthus Therapeutics' lead drug candidate DNTH103, a monoclonal antibody currently in Phase 2 clinical trials for the treatment of several autoimmune and inflammatory diseases. The analysts believe DNTH103 has the potential to be a best-in-class complement therapy and could drive significant value for the company.

  • Wells Fargo initiated coverage on Dianthus Therapeutics on Thursday, March 19, 2026.

The players

Dianthus Therapeutics

A clinical-stage biotechnology company developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

Wells Fargo & Company

A major American multinational financial services company that provides banking, investment, and mortgage products and services.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The initiation of coverage by Wells Fargo is a positive sign for Dianthus Therapeutics, as it suggests the investment bank sees significant potential in the company's lead drug candidate and its ability to deliver value for shareholders.